Mangoceuticals (NASDAQ:MGRX) Releases Quarterly Earnings Results

Mangoceuticals (NASDAQ:MGRX) issued its earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, FiscalAI reports. Mangoceuticals had a negative return on equity of 92.68% and a negative net margin of 4,794.60%.The company had revenue of $0.07 million during the quarter.

Mangoceuticals Stock Performance

Shares of MGRX stock traded up $0.00 on Friday, reaching $0.53. 20,873,608 shares of the company’s stock traded hands, compared to its average volume of 38,570,216. The company has a market capitalization of $9.18 million, a P/E ratio of -0.53 and a beta of 2.10. Mangoceuticals has a 12-month low of $0.16 and a 12-month high of $2.75. The business’s 50 day moving average price is $0.43 and its two-hundred day moving average price is $0.41.

Wall Street Analyst Weigh In

Several research firms have issued reports on MGRX. Weiss Ratings restated a “sell (e+)” rating on shares of Mangoceuticals in a report on Wednesday, June 24th. Wall Street Zen raised shares of Mangoceuticals to a “sell” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Mangoceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of Mangoceuticals in the fourth quarter worth approximately $25,000. Ikarian Capital LLC purchased a new stake in Mangoceuticals in the 4th quarter worth approximately $102,000. Boothbay Fund Management LLC acquired a new stake in shares of Mangoceuticals during the 4th quarter valued at $28,000. Armistice Capital LLC acquired a new stake in shares of Mangoceuticals during the 4th quarter valued at $1,137,000. Finally, Jane Street Group LLC purchased a new position in shares of Mangoceuticals during the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 56.72% of the company’s stock.

About Mangoceuticals

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.